Share:
Research Letter

Tildrakizumab: Successful Response in Two Patients with Psoriatic Arthritis

Author Affiliation(s)

Abstract

References

1. Nguyen CT, Bloch Y, Składanowska K, et al. Pathophysiology and inhibition of IL-23 signaling in psoriatic arthritis: A molecular insight. Clin Immunol. 2019 Sep; 206:15-22. doi: 10.1016/j.clim.2018.09.002. Epub 2018 Sep 6. PMID: 30196070; PMCID: PMC6401348. 2. Boehncke WH, Brembilla NC, Nissen MJ. Guselkumab: the First Selective IL-23 Inhibitor for Active Psoriatic Arthritis in Adults. Expert Rev Clin Immunol. 2021 Jan;17(1):5-13. doi: 10.1080/1744666X.2020.1857733. Epub 2020 Dec 7. PMID: 33251833.

Send mail to Author


Send Cancel